Intersect ENT Stock Price Target and Analyst Ratings (NASDAQ:XENT)

Analyst Price Target for XENT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$23.00

▼ -0.69% Downside Potential

This price target is based on 8 analysts offering 12 month price targets for Intersect ENT in the last 3 months. The average price target is $23.00, with a high forecast of $32.00 and a low forecast of $10.00. The average price target represents a -0.69% upside from the last price of $23.16.

Hold

The current consensus among 8 contributing investment analysts is to hold stock in Intersect ENT. This rating has held steady since May 2019, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/4/2019

0 strong buy ratings
3 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/3/2019

0 strong buy ratings
2 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

3/2/2020

0 strong buy ratings
3 buy ratings
6 hold ratings
1 sell ratings

Ratings as of

5/31/2020

0 strong buy ratings
3 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

8/29/2020

0 strong buy ratings
3 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

11/27/2020

0 strong buy ratings
3 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
3 buy ratings
4 hold ratings
1 sell ratings

Ratings as of

2/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/15/2021	Piper Sandler	Boost Price Target	Neutral	$17.00 ➝ $23.00	Medium	i
1/11/2021	Canaccord Genuity	Upgrade	Hold ➝ Buy	$18.00 ➝ $25.00	Low	i
12/3/2020	SVB Leerink	Boost Price Target	Market Perform	$18.00 ➝ $22.00	High	i
11/19/2020	BTIG Research	Upgrade	Neutral ➝ Buy	$32.00	High	i
11/3/2020	SVB Leerink	Lower Price Target	Market Perform	$19.50 ➝ $18.00	High	i
11/2/2020	Piper Sandler	Boost Price Target	In-Line ➝ Neutral	$16.00 ➝ $17.00	Medium	i
10/22/2020	Piper Sandler	Lower Price Target	Neutral	$17.00 ➝ $16.00	Medium	i
10/8/2020	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$19.00	High	i
8/7/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$30.00	High	i
8/5/2020	SVB Leerink	Boost Price Target	Market Perform	$18.50 ➝ $19.50	Medium	i
8/5/2020	Canaccord Genuity	Reiterated Rating	Hold	$18.00	High	i
8/4/2020	Piper Sandler	Boost Price Target	Neutral	$14.00 ➝ $17.00	High	i
8/4/2020	Oppenheimer	Reiterated Rating	Hold		Low	i Rating by Suraj Kalia at Oppenheimer Holdings Inc.
7/15/2020	SVB Leerink	Boost Price Target	Market Perform	$14.00 ➝ $18.50	Low	i
6/29/2020	SVB Leerink	Lower Price Target	Market Perform	$15.00 ➝ $14.00	High	i
6/23/2020	Oppenheimer	Initiated Coverage	Market Perform		High	i
6/10/2020	BTIG Research	Reiterated Rating	Hold		High	i
5/12/2020	SVB Leerink	Boost Price Target	Market Perform	$13.00 ➝ $15.00	High	i
5/12/2020	JPMorgan Chase & Co.	Lower Price Target	Overweight	$28.00 ➝ $18.00	High	i
5/12/2020	Piper Sandler	Lower Price Target	Neutral	$23.00 ➝ $14.00	Medium	i
5/12/2020	Canaccord Genuity	Downgrade	Buy ➝ Hold		High	i
4/15/2020	Bank of America	Downgrade	Buy ➝ Underperform	$28.00 ➝ $10.00	High	i
4/14/2020	SVB Leerink	Lower Price Target	Market Perform	$28.00 ➝ $13.00	High	i
4/13/2020	BTIG Research	Reiterated Rating	Hold		Medium	i
3/24/2020	BTIG Research	Reiterated Rating	Hold		Low	i
2/25/2020	Canaccord Genuity	Reiterated Rating	Buy	$30.00	High	i
12/20/2019	JPMorgan Chase & Co.	Boost Price Target	Overweight	$25.00 ➝ $28.00	Medium	i
11/1/2019	Piper Jaffray Companies	Set Price Target	Hold	$21.00	N/A	i Rating by Matthew O'Brien at Piper Jaffray Companies
8/2/2019	Guggenheim	Downgrade	Buy ➝ Neutral		High	i
8/2/2019	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$30.00 ➝ $17.00	High	i
7/10/2019	Northland Securities	Upgrade	Under Perform ➝ Market Perform	$20.00	Low	i
6/21/2019	Berenberg Bank	Downgrade	Buy ➝ Hold	$35.00 ➝ $27.00	High	i
5/7/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$41.00 ➝ $29.00	High	i Rating by R. Newitter at SVB Leerink LLC
5/7/2019	Northland Securities	Downgrade	Market Perform ➝ Under Perform	$28.00 ➝ $20.00	High	i
2/26/2019	BTIG Research	Reiterated Rating	Hold		High	i
2/26/2019	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $40.00	Medium	i
11/5/2018	Northland Securities	Reiterated Rating	Hold	$28.00	High	i
10/17/2018	Northland Securities	Reiterated Rating	Hold	$28.00	Low	i
8/2/2018	BTIG Research	Reiterated Rating	Hold		High	i
8/1/2018	Canaccord Genuity	Reiterated Rating	Buy		High	i
8/1/2018	Piper Jaffray Companies	Lower Price Target	Overweight	$45.00 ➝ $40.00	High	i
5/7/2018	Canaccord Genuity	Reiterated Rating	Buy		Low	i
5/2/2018	Northland Securities	Reiterated Rating	Hold	$32.00	Low	i
5/2/2018	BTIG Research	Reiterated Rating	Hold		Low	i
5/2/2018	JPMorgan Chase & Co.	Reiterated Rating	Overweight	$48.00	Low	i
4/20/2018	Berenberg Bank	Initiated Coverage	Buy		Low	i
3/1/2018	Guggenheim	Reiterated Rating	Buy		Low	i
1/2/2018	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight		High	i
12/15/2017	Guggenheim	Reiterated Rating	Buy	$41.00	Low	i
12/11/2017	Canaccord Genuity	Reiterated Rating	Buy	$36.00	Medium	i
11/7/2017	BTIG Research	Reiterated Rating	Hold		N/A	i
11/3/2017	Northland Securities	Reiterated Rating	Hold	$25.00	N/A	i Rating by Suraj Kalia at Northland Securities
9/13/2017	Canaccord Genuity	Boost Price Target	Buy	$32.00 ➝ $37.00	Low	i
9/11/2017	Bank of America	Boost Price Target	Buy	$33.00 ➝ $40.00	High	i
8/22/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$35.00	Low	i
8/2/2017	Canaccord Genuity	Reiterated Rating	Buy	$32.00	Medium	i Rating by Kyle Rose at Canaccord Genuity
8/2/2017	Deutsche Bank Aktiengesellschaft	Set Price Target	Buy	$27.00 ➝ $31.00	High	i Rating by Brittany Henderson at Deutsche Bank Aktiengesellschaft
8/2/2017	Northland Securities	Reiterated Rating	Hold	$25.00	High	i Rating by Suraj Kalia at Northland Securities
5/31/2017	Northland Securities	Downgrade	Outperform ➝ Market Perform		Medium	i
5/10/2017	William Blair	Reiterated Rating	Outperform		Low	i Rating by K. Krum at William Blair
5/4/2017	Northland Securities	Boost Price Target	Outperform	$17.00 ➝ $22.00	High	i
5/3/2017	Canaccord Genuity	Reiterated Rating	Buy		High	i Rating by Kyle Rose at Canaccord Genuity
5/3/2017	Wedbush	Boost Price Target	Outperform ➝ Outperform	$25.00 ➝ $26.00	High	i
3/13/2017	Northland Securities	Reiterated Rating	Buy	$17.00	Low	i
3/8/2017	Canaccord Genuity	Initiated Coverage	Buy	$17.00	Low	i Rating by Kyle Rose at Canaccord Genuity
3/6/2017	Deutsche Bank Aktiengesellschaft	Upgrade	Hold ➝ Buy	$15.00 ➝ $19.00	N/A	i Rating by Brittany Henderson at Deutsche Bank Aktiengesellschaft
2/24/2017	Wedbush	Reiterated Rating	Outperform	$25.00	N/A	i
2/21/2017	Canaccord Genuity	Reiterated Rating	Buy	$16.00	N/A	i Rating by Kyle Rose at Canaccord Genuity
1/23/2017	Canaccord Genuity	Set Price Target	Buy	$16.00	N/A	i Rating by Kyle Rose at Canaccord Genuity
1/11/2017	Wedbush	Reiterated Rating	Outperform	$25.00	N/A	i
12/6/2016	Guggenheim	Initiated Coverage	Buy	$20.00	N/A	i
11/4/2016	SVB Leerink	Reiterated Rating	Outperform	$21.00 ➝ $14.00	N/A	i
11/2/2016	Canaccord Genuity	Set Price Target	Buy	$20.00	N/A	i Rating by Kyle Rose at Canaccord Genuity
11/2/2016	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$25.00 ➝ $16.00	N/A	i
10/18/2016	Deutsche Bank Aktiengesellschaft	Set Price Target	Hold	$17.00	N/A	i Rating by Brittany Henderson at Deutsche Bank Aktiengesellschaft
10/6/2016	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Hold	$17.00	N/A	i
9/23/2016	Wedbush	Reiterated Rating	Outperform	$25.00	N/A	i
8/26/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$21.00	N/A	i
8/4/2016	Canaccord Genuity	Reiterated Rating	Buy	$20.00	N/A	i Rating by Kyle Rose at Canaccord Genuity
8/4/2016	BTIG Research	Reiterated Rating	Hold	$14.00	N/A	i Rating by Sean Lavin at BTIG Research
8/3/2016	Wedbush	Reiterated Rating	Outperform	$25.00	N/A	i
7/18/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by Kyle Rose at Canaccord Genuity
7/18/2016	Wedbush	Reiterated Rating	Outperform	$25.00	N/A	i
7/12/2016	BTIG Research	Initiated Coverage	Neutral		N/A	i
3/29/2016	Northland Securities	Initiated Coverage	Outperform	$26.00	N/A	i
3/24/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by Kyle Rose at Canaccord Genuity
3/24/2016	SVB Leerink	Reiterated Rating	Buy		N/A	i Rating by Richard Newitter at SVB Leerink LLC
3/24/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$29.00	N/A	i

(Data available from 2/26/2016 forward)

Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.

Today's Range

Now: $23.16

$23.16

$24.35

50 Day Range

MA: $24.21

$21.63

$26.62

52 Week Range

Now: $23.16

$5.97

$26.98

Volume

208,526 shs

Average Volume

197,795 shs

Market Capitalization

$757.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.34

Frequently Asked Questions

What sell-side analysts currently cover shares of Intersect ENT?

The following Wall Street sell-side analysts have issued research reports on Intersect ENT in the last twelve months: Bank of America Co., BTIG Research, Canaccord Genuity, Guggenheim, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Piper Sandler, and SVB Leerink LLC.
View the latest analyst ratings for XENT.

What is the current price target for Intersect ENT?

7 Wall Street analysts have set twelve-month price targets for Intersect ENT in the last year. Their average twelve-month price target is $23.00, suggesting a possible downside of 0.7%. BTIG Research has the highest price target set, predicting XENT will reach $32.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $10.00 for Intersect ENT in the next year.
View the latest price targets for XENT.

What is the current consensus analyst rating for Intersect ENT?

Intersect ENT currently has 1 sell rating, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in XENT, but not buy more shares or sell existing shares.
View the latest ratings for XENT.

What other companies compete with Intersect ENT?

Other companies that are similar to Intersect ENT include NuVasive, AtriCure, Inovio Pharmaceuticals, Axonics Modulation Technologies, Pulmonx, Silk Road Medical, Cardiovascular Systems, Luminex, GenMark Diagnostics, Alphatec, Atrion, MiMedx Group, Cerus, OrthoPediatrics and SI-BONE.

How do I contact Intersect ENT's investor relations team?

Intersect ENT's physical mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider's listed phone number is 650-641-2100 and its investor relations email address is [email protected] The official website for Intersect ENT is www.intersectent.com.

NASDAQ:XENT - Intersect ENT Stock Price Target and Predictions

Analyst Price Target for XENT

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Intersect ENT?

What is the current price target for Intersect ENT?

What is the current consensus analyst rating for Intersect ENT?

What other companies compete with Intersect ENT?

How do I contact Intersect ENT's investor relations team?